{
  "docId": "019de070-701b-7388-a208-3e38cd293d9a",
  "docSlug": "f771dd63c4f3642a1d968d8585ded9c7",
  "documentTitle": "Evotec | Investor Day Presentation Deck | 103 slides",
  "authorId": "evotec",
  "authorName": "Evotec",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 103,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a two-column layout: a numbered list of upcoming events on the left and a series of pull-quotes from internal experts on the right.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-701b-7388-a208-3e38cd293d9a/23",
  "deckHref": "/decks/019de070-701b-7388-a208-3e38cd293d9a",
  "deckJsonHref": "/decks/019de070-701b-7388-a208-3e38cd293d9a.json",
  "deckAnchorHref": "/decks/019de070-701b-7388-a208-3e38cd293d9a#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.42,
        "x": 0.03,
        "y": 0.28
      },
      "kind": "list",
      "text": "1. Phase IIb with Bayer in RCC (Eliapixant)\n2. Phase II with Bayer in Overactive bladder (Eliapixant)\n3. Phase II with Bayer in Endometriosis (Eliapixant)\n4. Phase II initiation with BI in Oncology / Pain\n5. Phase II with Bayer in Gynaecology (B1 antagonist)\n6. Phase I initiation in Chikungunya virus\n7. Phase I with BMS in CNS\n8. Phase I with Exscientia in Oncology (A2a)\n9. Phase I with Bayer in Gynaecology (P2X4)\n10. Phase I with Sanofi in Immuno-oncology\n11. Phase I in HBV Cure\n12. Multiple co-owned equity companies will progress in clinic (e.g. Topas, Forge, Carrick, Fibrocor, QRbeta, ...)",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "545ce291-2e73-4ab6-9ba7-00b0fa6685d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.51,
        "x": 0.46,
        "y": 0.45
      },
      "kind": "quote",
      "text": "True innovation – an antibody to be used as both: targeted therapy, and prophylactic treatment - Florian von Groote-Bidlingmaier (Evotec)",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "515cb602-082a-4784-85c2-a7c0b6c70b94",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.51,
        "x": 0.46,
        "y": 0.71
      },
      "kind": "quote",
      "text": "P2X3 is a pipeline in a molecule. E.g. in refractory chronic cough with its selectivity and side effect profile. - Adam Davenport (Evotec)",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ae3f8a3-bc8c-4f73-bb51-860b5f4f0cf3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.51,
        "x": 0.46,
        "y": 0.28
      },
      "kind": "quote",
      "text": "Beta cell therapy is the most promising approach to cure diabetes. IPSCs have game changing potential, they fast forward many key questions for new drugs. - Andreas Scheel (Evotec) & Rainer Kuhn (Evotec)",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bcf1a2f2-181f-4025-b71e-c5e93113447d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.51,
        "x": 0.46,
        "y": 0.6
      },
      "kind": "quote",
      "text": "Potent molecule with sustained activity to achieve HBV functional cure. - Antoine Alam (Evotec)",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bec179af-a2fe-4ec6-ae3a-dcec54f0db92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.25,
        "y": 0.1
      },
      "kind": "title",
      "text": "Pipeline will strongly gain visibility with no clinical costs for us",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3b2507c-81ae-49ba-80bd-9126dd473a1a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.25,
        "y": 0.17
      },
      "kind": "title",
      "text": "Overview of pipeline and selected upcoming events & internal champions",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8db1e383-ef48-4cbd-826f-9f7e1a2dcddb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "16855a90-9842-44b4-b93b-5b54e14d3f1a",
      "evidence": "list/numbered: 1. Phase IIb with Bayer in RCC (Eliapixant) 2. Phase II with Bayer in Overactive bladder (Eliapixant) 3. Phase II with Bayer in Endometriosis (Eliapixant) 4. Phase II initiation with BI in Oncology / Pain",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 30,
      "from": 15,
      "beatId": "bff745b7-4060-47df-8173-1e462b2c6fda",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The deck provides evidence of Evotec's strategy delivering growth and value potential.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}